1
00:00:00,000 --> 00:00:03,500
VK2735 activates GIP and GLP-1 receptors.

2
00:00:03,500 --> 00:00:09,750
Its research includes different formulations, making the route of administration an important part of

3
00:00:09,750 --> 00:00:13,250
every evidence claim.

4
00:00:13,250 --> 00:00:20,333
The phase two VENTURE study tested the injectable formulation against placebo in adults with obesity or

5
00:00:20,333 --> 00:00:23,833
overweight and a related condition, excluding diabetes.

6
00:00:23,833 --> 00:00:28,917
Over 13 weeks, the study reported greater body-weight reduction with VK2735.

7
00:00:28,917 --> 00:00:32,417
The most common adverse events were gastrointestinal.

8
00:00:32,417 --> 00:00:35,917
These are short-term trial findings.

9
00:00:35,917 --> 00:00:41,375
An oral formulation needs its own evidence on absorption, tolerability, and outcomes.

10
00:00:41,375 --> 00:00:48,042
Results from an injectable study cannot establish equivalent performance for a tablet or an unrelated

11
00:00:48,042 --> 00:00:51,542
research product.